Page 8 - Mapa infectii 2025
P. 8

Protec ie împotriva gripei


                                                   pe parcursul întregului sezon


                                                   CHIAR SUB NASUL TĂU


                                                   Fluenz - singurul vaccin gripal cu administrare intranazală,
                                                   asigură protec ia copiilor și adolescen ilor cu vârsta cuprinsă
                                                   între 24 de luni și mai pu in de 18 ani împotriva gripei.




                        Fluenz asigură protec ie                              Fluenz este singurul vaccin
                        împotriva gripei timp de                              gripal intranazal care asigură
                        până la 12 luni. 3                                    un răspuns imun pe 3 căi.   1,4-7





                        Fluenz poate reduce spitalizările                     Modul de administrare Fluenz
                        copiilor din cauza tuturor                            reușește să crească ratele de
                        tulpinilor de gripă cu până la                        vaccinare conform autorită ilor
                        63% comparativ cu IIV.*   8-11                        de sănătate, fiind preferat de
                                                                              părin i. 2,4,12-18

    *IIV - inactivated influenza vaccine - vaccin gripal cu virus inactivat
    Referin e: 1. Fluenz Trivalent, suspensie de spray nazal pentru vaccin gripal (virus viu atenuat, administrare nazală). Rezumatul caracteristicilor produsului. AstraZeneca UK Limited; 2. UK Health Security Agency.
    Chapter 19: Influenza. In: Ramsay M, ed. Immunisation against infectious disease. Department of Health and Social Care, National Health Service. Updated November 10, 2023. Accessed October 2, 2024.
    https://assets.publishing.service.gov.uk/media/654cf306014cc90010677371/Green-book-chapter-19-influenza-_3November2023.pdf; 3. Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided
    by live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2008;27(8):744-748. doi:10.1097/INF.0b013e318174e0f8; 4. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce
    similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845-853. doi:10.1093/infdis/jir43; 5. Beyer WEP, Palache AM, de Jong JC, Osterhaus
    ADME. Coldadapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine. 2002;20(9-10):1340-1353.
    doi:10.1016/s0264-410x(01)00471-6; 6. Mohn KGI, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin lmmunother. 2018;14(3):571-578.
    doi:10.1080/21645515.2017.1377376; 7. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza
    vaccines. Scand J lmmunol. 2004;59(1):1-15. doi:10.1111/j.0300-9475.2004.01382.x; 8. National Services Scotland. Flu vaccine effectiveness in Scottish primary school age children from the 2015/16 season.
    Health Protection Scotland. 2016. Accessed October 2, 2024. https://webarchive.nrscotland.gov.uk/20190221073445/https://www.hps.scot.nhs.uk/resourcedocument.aspx?id= 5529; 9. Boddington NL,
    Warburton F, Zhao H, et al. Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015-2016 influenza season—a testnegative case-control
    study. Epidemiol Infect. 2019;147:e201. doi:10.1017/S0950268819000876; 10. Boddington NL, Mangtani P, Zhao H, et al. Live-attenuated influenza vaccine effectiveness against hospitalization in children aged
    2-6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14-2015/16. Influenza Other Respir Viruses. 2022;16(5):897-905. doi:10.1111/irv.12990; 11. Pebody RG, Zhao H,
    Whitaker HJ, et al. Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England. Vaccine. 2020;38(2):158-164. doi:10.1016/j.vaccine.2019.10.035; 12. Nohynek
    H, Baum U, Jaaskelainen N, Ikonen N, Sundman J. Seasonal influenza vaccine coverage, especially live attenuated vaccine coverage, increases steadily among children in Finland according to a nationwide
    register-based cohort study. Paper presented at: 2019 ESPID annual meeting; May 6-May 11, 2019; Ljubljana, Slovenia; 13. Seasonal influenza vaccination coverage: season 2023-2024, children aged 2 years, all
    influenza vaccines. Finnish Institute for Health and Welfare. Updated September 2, 2024. Accessed October 2, 2024. https://www.thl.fi/roko/vaccreg/atlas/public/atlas-en.html?show=influenza; 14. Seasonal
    influenza vaccination coverage:season 2023-2024, children aged 3-6 years, all influenza vaccines. Finnish Institute for Health and Welfare. Updated September 2, 2024. Accessed October 2, 2024.
    https://www.thl.fi/roko/vaccreg/atlas/public/atlas-en.html?show=influenza; 15. National Institute for Health and Care Excellence. Vaccine uptake in the general population. Interventions to increase vaccine uptake
    by targeting acceptability. Department of Health and Social Care, National Health Service. 2022. Accessed October 2, 2024. https://www.nice.org.uk/guidance/ng218; 16. Children’s flu vaccine. Department of
    Health and Social Care, National Health Service. Updated December 13, 2023. Accessed October 2, 2024. https://www.nhs.uk/conditions/vaccinations/child-flu-vaccine; 17. Public Health England. Extension of
    the influenza immunisation programme to children in England: experiences of using live attenuated influenza vaccine (LAIV) in school age children 2013-16. Department of Health and Social Care, National Health
    Service. 2016. Accessed October 2, 2024.https://assets.publishing.service.gov.uk/media/5c2f4ce1e5274a65cc0f5d69/Extension_of_the_Influenza_immunisation_programme_to_children_in_England.pdf; 18.
    Harris C, Cottrell S, Perry M, etal. A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery
    school immunisation sessions. Vaccine. 2023;41(18):2990-2995. doi:10.1016/j.vaccine.2023.03.075.
    Acest material este destinat profesioniștilor din domeniul sănătăţii
    Medicament eliberat pe bază de prescrip ie medicală.
    Evenimentele adverse pot fi raportate online https://contactazmedical.astrazeneca.com, sau la adresa farmacovigilenta@astrazeneca.com
    Primi i acest material în urma acordului dvs. de a primi comunicări de la AstraZeneca Pharma SRL.
    Dacă nu mai dori i să primi i mesaje de la noi, vă rugăm să vă dezabona i AICI.
    Mai multe informa ii privind modul în care AstraZeneca prelucrează datele dvs. cu caracter personal, care sunt drepturile dvs. și cum le pute i
    exercita sunt disponibile în Nota de Informare privind prelucrarea datelor cu caracter personal disponibilă AICI.
    RO-26279/06.2025


                      Pentru informa ii suplimentare, vă rugăm să
                      consulta i versiunea actualizată a Rezumatului                                ASTRAZENECA PHARMA S.R.L.
                      Caracteristicilor Produsului, scanând codul QR                Str. Tipografilor 1A, MUSE Offices, Et. 2 si 3, 013714, sector 1,
                                                                                                   București, Tel.: +40 21 317 60 41;
                                                                                                Email: office.romania@astrazeneca.com
   3   4   5   6   7   8   9   10   11   12   13